Photo
January 17, 2021
Photo courtesy of Merck.
Merck will tap Janux’s Tumor Activated T Cell Engager (TRACTr) tech to engineer new drug candidates against two cancer targets selected by Merck.
Stories this photo appears in:
Janux Partners With Merck
BIOTECH: Deal Worth More Than $1 Billion
